PMID- 36238838 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221015 IS - 1792-1082 (Electronic) IS - 1792-1074 (Print) IS - 1792-1074 (Linking) VI - 24 IP - 4 DP - 2022 Oct TI - Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study. PG - 375 LID - 10.3892/ol.2022.13495 [doi] LID - 375 AB - Sarcopenia often affects patients with various types of cancer, and has been reported to affect patient prognosis and therapeutic effects. However, to the best of our knowledge, there are no reports on the relationship between gemcitabine plus nab-paclitaxel combination therapy (GnP) and sarcopenia in patients with unresectable pancreatic cancer. The present study analyzed the relationship between overall survival (OS), progression-free survival (PFS), response rate, disease control rate, adverse events (AEs) and sarcopenia in patients with pancreatic cancer treated with GnP. A total of 121 consecutive patients with advanced pancreatic cancer who received GnP as first-line chemotherapy between January 2015 and December 2017 were retrospectively analyzed. GnP consisted of 1,000 mg/m(2) gemcitabine and 125 mg/m(2) nab-paclitaxel, which were administered on days 1, 8 and 15 every 4 weeks. The skeletal muscle index (SMI) was calculated using bioimpedance analysis (BIA) as an index of sarcopenia prior to GnP. The patients were divided into sarcopenia (n=41) and non-sarcopenia (n=80) groups using cutoff values of 8.87 and 6.42 kg/m(2) for male and female patients, respectively. The sarcopenia and non-sarcopenia groups had a median OS of 8.1 and 13.9 months, respectively [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.53-1.20], and a median PFS of 4.3 and 6.3 months, respectively (HR 0.63; 95% CI 0.42-0.95). The response and disease controls rate were not statistically different between the groups (20 vs. 32%, P=0.20; 81 vs. 80%, P=1.0). In addition, comparison of common grade 3 and 4 AEs between the two groups revealed no statistically significant differences. In conclusion, the results of the present study indicated that SMI obtained by BIA may be a predictor of treatment response and prognosis in patients with advanced pancreatic cancer who undergo GnP. CI - Copyright: (c) Tozuka et al. FAU - Tozuka, Yuichiro AU - Tozuka Y AD - Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan. AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Ueno, Makoto AU - Ueno M AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Kobayashi, Satoshi AU - Kobayashi S AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Morimoto, Manabu AU - Morimoto M AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Fukushima, Taito AU - Fukushima T AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Sano, Yusuke AU - Sano Y AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Kawano, Kuniyuki AU - Kawano K AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Hanaoka, Akane AU - Hanaoka A AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Tezuka, Shun AU - Tezuka S AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Asama, Hiroyuki AU - Asama H AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Moriya, Satoshi AU - Moriya S AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Morinaga, Soichiro AU - Morinaga S AD - Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Ohkawa, Shinichi AU - Ohkawa S AD - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan. FAU - Maeda, Shin AU - Maeda S AD - Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan. LA - eng PT - Journal Article DEP - 20220908 PL - Greece TA - Oncol Lett JT - Oncology letters JID - 101531236 PMC - PMC9494620 OTO - NOTNLM OT - AEs OT - GnP OT - bioimpedance method OT - chemotherapy OT - efficacy OT - pancreatic cancer OT - sarcopenia OT - survival OT - treatment response COIS- Dr Ueno and Dr Kobayashi reports grants and personal fees from Taiho Pharmaceutical. All the other authors declare that they have no competing interests. EDAT- 2022/10/15 06:00 MHDA- 2022/10/15 06:01 PMCR- 2022/09/08 CRDT- 2022/10/14 03:12 PHST- 2022/04/28 00:00 [received] PHST- 2022/08/05 00:00 [accepted] PHST- 2022/10/14 03:12 [entrez] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/15 06:01 [medline] PHST- 2022/09/08 00:00 [pmc-release] AID - OL-24-04-13495 [pii] AID - 10.3892/ol.2022.13495 [doi] PST - epublish SO - Oncol Lett. 2022 Sep 8;24(4):375. doi: 10.3892/ol.2022.13495. eCollection 2022 Oct.